Departments of Neuroscience and Biophysics, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Institute for Protein Innovation, 4 Blackfan Circle, Boston, MA, 02115, USA.
Nat Commun. 2022 Aug 6;13(1):4582. doi: 10.1038/s41467-022-32212-4.
γ-Aminobutyric acid type A (GABA) receptors are pentameric ligand-gated ion channels abundant in the central nervous system and are prolific drug targets for treating anxiety, sleep disorders and epilepsy. Diverse small molecules exert a spectrum of effects on γ-aminobutyric acid type A (GABA) receptors by acting at the classical benzodiazepine site. They can potentiate the response to GABA, attenuate channel activity, or counteract modulation by other ligands. Structural mechanisms underlying the actions of these drugs are not fully understood. Here we present two high-resolution structures of GABA receptors in complex with zolpidem, a positive allosteric modulator and heavily prescribed hypnotic, and DMCM, a negative allosteric modulator with convulsant and anxiogenic properties. These two drugs share the extracellular benzodiazepine site at the α/γ subunit interface and two transmembrane sites at β/α interfaces. Structural analyses reveal a basis for the subtype selectivity of zolpidem that underlies its clinical success. Molecular dynamics simulations provide insight into how DMCM switches from a negative to a positive modulator as a function of binding site occupancy. Together, these findings expand our understanding of how GABA receptor allosteric modulators acting through a common site can have diverging activities.
γ-氨基丁酸 A 型 (GABA) 受体是中枢神经系统中五聚体配体门控离子通道,是治疗焦虑、睡眠障碍和癫痫的重要药物靶点。多种小分子通过作用于经典苯二氮䓬结合位点,对 GABA 受体产生广泛的影响。它们可以增强 GABA 的反应,减弱通道活性,或拮抗其他配体的调制。这些药物作用的结构机制尚未完全了解。在这里,我们展示了 GABA 受体与唑吡坦(一种正变构调节剂和广泛使用的催眠药)和 DMCM(一种具有致惊厥和焦虑特性的负变构调节剂)复合物的两个高分辨率结构。这两种药物共享位于 α/γ 亚基界面的细胞外苯二氮䓬结合位点和位于 β/α 界面的两个跨膜结合位点。结构分析揭示了唑吡坦的亚型选择性的基础,这是其临床成功的基础。分子动力学模拟提供了对 DMCM 如何随着结合位点占有率的变化从负变构调节剂转变为正变构调节剂的深入了解。总之,这些发现扩展了我们对通过共同结合位点起作用的 GABA 受体变构调节剂如何具有不同活性的理解。